metricas
covid
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Factores microbiológicos que afectan a la erradicación de Helicobacter pylori ...
Journal Information
Vol. 20. Issue 9.
Pages 431-434 (November 2002)
Share
Share
Download PDF
More article options
Vol. 20. Issue 9.
Pages 431-434 (November 2002)
Full text access
Factores microbiológicos que afectan a la erradicación de Helicobacter pylori en población adulta y pediátrica
Microbiological factors that influence the eradication of Helicobacter pylori in adults and children
Visits
8332
Diego Domingoa,1
Corresponding author
ddomingo@helicobacterspain.com

Correspondencia: Dr. D. Domingo. Servicio de Microbiología. Hospital Universitario de La Princesa. Diego de León, 62. 28006 Madrid. España.
, Teresa Alarcóna, Alba Edith Vegab, José Ángel Garcíaa, María Josefa Martínezc, Manuel López-Breaa
a Servicio de Microbiología. Hospital Universitario de La Princesa. Madrid
b Área de Microbiología. Universidad Nacional de San Luis, Chacabuco y Pedernera. San Luis. Argentina
c Servicio de Gastroenterología. Hospital del Niño Jesús. Madrid. España
This item has received
Article information
Objetivos

Estudiar factores microbiológicos como la sensibilidad a antimicrobianos y factores de virulencia de Helicobacter pylori relacionados con la erradicación del microorganismo de la mucosa gástrica, tanto en población pediátrica como adulta.

Métodos

Se obtuvieron 55 cepas aisladas a partir del cultivo de biopsias de 16 pacientes pediátricos y de 39 adultos. La sensibilidad antibiótica se realizó mediante el método de dilución en agar y el estudio de los factores de virulencia, gen cagA y los alelos s1 y s2 del gen vacA mediante reacción en cadena de la polimerasa (PCR). El seguimiento tras el tratamiento que se instauró con amoxicilina, claritromicina y omeprazol se realizó mediante la prueba del aliento con urea marcada. Se estudió la relación entre la concentración inhibitoria mínima (CIM) a amoxicilina y claritromicina y la presencia de estos factores de virulencia con la erradicación del microorganismo.

Resultados

La erradicación fue del 69% (38/55), 71,7% en adultos y 62,5% en niños. La resistencia a claritromicina y amoxicilina fue 14,5 y 0%, respectivamente. Las tasas de erradicación globales en relación con las variables estudiadas fueron del 75 y 53% en cepas con CIM de amoxicilina ≤ 0,016 mg/l y CIM de amoxicilina ≥ 0,032 mg/l (intervalo ≤ 0,008-0,5) (p > 0,05), 79 y 12% en cepas con CIM de claritromicina < 1 mg/l y CIM de claritromicina ≥ 1 mg/l (intervalo ≤ 0,008-64) (p < 0,05), 79 y 54% en cepas cagA+ y cagA– (p > 0,05) y 82 y 62% en cepas s1 y s2 (p > 0,05), respectivamente.

Conclusiones

La infección por cepas con CIM más altas a amoxicilina y claritromicina y por aislamientos cagA– y vacA s2 se relacionaron con tasas más bajas de erradicación de H. pylori, tanto en población adulta como infantil en la terapia con amoxicilina, claritromicina y omeprazol.

Palabras clave:
Helicobacter pylori
Erradicación
Resistencia
Factores de virulencia
Aim

To study microbiological factors of Helicobacter pylori, such as antimicrobial susceptibility and virulence, which affect the eradication of the microorganism in gastric mucosa of adult and pediatric patients.

Methods

Fifty-five H. Pylori strains were isolated from culture of biopsy specimens from 39 adult and 16 pediatric patients. Antibiotic susceptibility was determined by agar dilution and study of virulence factors (cagA gene and alleles s1 and s2 of the vacA gene) by PCR. Outcome of treatment with amoxicillin (AMX), clarithromycin (CLR) and omeprazole was assessed by the urea breath test. We studied the relation of minimum inhibitory concentration (MIC) of AMX and CLR and presence of virulence factors with eradication of the microorganism.

Results

The eradication rate was 69% (38/55), 71.7% in adults and 62.5% in children. Resistance to CLR and AMX was 14.5% and 0%, respectively. Overall eradication rates with respect to the variables studied were: 75% and 53% in strains with AMX MICs of ≤ 0.01 6mg/L and ≥ 0.032 mg/L (range ≤ 0.008-0.5) (p > 0.05), 79% and 12% in strains with claritromicina MICs of < 1 mg/L and ≥ 1mg/L (range ≤ 0.008-64) (p < 0.05), 79% and 54% in cagA??and cagA– strains (p > 0.05) and 82% and 62% in s1 and s2 strains (p > 0.05), respectively.

Conclusions

H. pylori strains with higher amoxicillin and clarithromycin MICs, and cagA– and vacA s2 strains were related with lower rates of eradication in both adult and pediatric populations treated with amoxicillin, clarythromycin and omeprazole.

Key words:
Helicobacter pylori
Eradication
Resistance
Virulence factors
Full text is only aviable in PDF
Bibliografía
[1.]
G.I. Pérez-Pérez.
Helicobacter buenos y malos.
pp. 31-40
[2.]
P. Malfertheiner, F. Megraud, C. O’Morain, A.P. Hungin, R. Jones, A. Axon, et al.
Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 consensus report.
Aliment Pharmacol Ther, 16 (2002), pp. 167-180
[3.]
Y. Glupczynski, A. Burette.
Drug therapy for Helicobacter pylori infection: Problems and pitfalls.
Am J Gastroenterol, 85 (1990), pp. 1545-1551
[4.]
T. Alarcon, D. Domingo, M. Lopez-Brea.
Antibiotic resistance problems with Helicobacter pylori.
Int J Antimicrob Agents, 12 (1999), pp. 19-26
[5.]
M. Lopez-Brea, M.J. Martinez, D. Domingo, T. Alarcon.
A 9 year study of clarithromycin and metronidazole resistance in Helicobacter pylori from Spanish children.
J Antimicrob Chemother, 48 (2001), pp. 295-297
[6.]
A. Covacci, S. Censini, M. Bugnoli, R. Petracca, D. Burroni, G. Macchia, et al.
Molecular characterization of the 128-KDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer.
Proc Natl Acad Sci (USA), 90 (1993), pp. 5791-5795
[7.]
J.C. Atherton, P. Cao, R.M. Peek, M.K.R. Tummuru, M.J. Blazer, T.L. Cover.
Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration.
J Biol Chem, 270 (1995), pp. 17771-17777
[8.]
G. Figueroa, M. Troncoso, M.S. Toledo, G. Faundez, R. Acuna.
Prevalence of serum antibodies to Helicobacter pylori VacA and CagA gastric disease in Chile.
J Med Microbiol, 51 (2002), pp. 300-304
[9.]
J.M. Kim, J.S. Kim, H.C. Jung, I.S. Song, C.Y. Kim.
Virulence factors of Helicobacter pylori in Korean isolates do not influence proinflammatory cytokine gene expression and apoptosis in human gastric epithelial cells, nor do these factors influence the clinical outcome.
J Gastroenterol, 35 (2000), pp. 947-948
[10.]
D. Domingo, T. Alarcón, N. Prieto, M. López-Brea.
Relación entre sensibilidad antibiótica y factores de virulencia en aislamientos clínicos de Helicobacter pylori.
Rev Esp Quimioter, 12 (1999), pp. 340-345
[11.]
K. Wilson, et al.
Preparation of genomic DNA from bacteria.
pp. 2.4.1-2.4.5
[12.]
A. Covacci, R. Rappuoli.
PCR amplification of H. pylori gene sequences.
pp. 94-111
[13.]
NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania, (2001), pp. 19087-19898
[14.]
Y. Glupczynski, F. Megraud, M. Lopez-Bream, L.P. Andersen.
European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori.
Eur J Clin Microbiol Infect Dis, 20 (2001), pp. 820-823
[15.]
F. Gottrand, N. Kalach, C. Spyckerelle, D. Guimber, J.F. Mougenot, P. Tounian, et al.
Omeprazole combined with amoxicillin and clarithromycin in the eradication of Helicobacter pylori in children with gastritis: A prospective randomized double-blind trial.
J Pediatr, 139 (2001), pp. 622-623
[16.]
E. Kawakami, S.K. Ogata, A.C. Portorreal, A.M. Magni, M.L. Pardo, F.R. Patricio.
Triple therapy with clarithromycin, amoxicillin and omeprazole for Helicobacter pylori eradication in children and adolescents.
Arq Gastroenterol, 38 (2001), pp. 203-206
[17.]
B.C. Wong, F.Y. Chang, S. Abid, Z. Abbas, B.R. Lin, C. Van Rensburg, et al.
Triple therapy with clarithromycin, omeprazole and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa.
Aliment Pharmacol Ther, 11 (2000), pp. 1529-1535
[18.]
P.M. Neville, S. Barrowclough, W. Crocombe, A.T. Axon, M. Wrangstadh, P. Moayyedi.
Randomized study of the efficacy of omeprazole and clarithromycin with either amoxicillin or metronidazole in the eradication of Helicobacter pylori in screened primary care patients.
Dig Liver Dis, 33 (2001), pp. 392
[19.]
M. Lopez-Brea, D. Domingo, I. Sanchez, T. Alarcon.
Evolution of the resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolates from Spain.
J Antimicrob Chemother, 40 (1997), pp. 279-281
[20.]
D. Domingo, T. Alarcon, N. Prieto, I. Sanchez, M. Lopez-Brea.
cagA and vacA status of Spainsh Helicobacter pylori clinical isolates.
J Clin Microbiol, 37 (1999), pp. 2113-2114
[21.]
S.D. Georgopoulos, S.D. Ladas, S. Karatapanis, A. Mentis, C. Spiliadi, V. Artikis, et al.
Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin, and clarithromycin.
Dig Dis Sci, 45 (2000), pp. 63-67
[22.]
J. Tankovic, D. Lamarque, C. Lascols, C.J. Soussy, J.C. Delchier.
Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy.
Aliment Pharmacol Ther, 15 (2001), pp. 707-713
[23.]
S.K. Poon, C.S. Chang, J. Su, C.H. Lai, C.C. Yang, G.H. Chen, et al.
Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies.
Aliment Pharmacol Ther, 16 (2002), pp. 291-296
[24.]
M.E. Street, P. Caruana, C. Caffarelli, W. Magliani, M. Manfredi, F. Fornaroli, et al.
Antibiotic resistance and antibiotic sensitivity based treatment in Helicobacter pylori infection: Advantages and outcome.
Arch Dis Child, 84 (2001), pp. 419-422
[25.]
L.J. Van Doorn, W. Quint, P. Schneberger, G.N.J. Tytgat, W.A. deBoer.
The only good Helicobacter pylori is a dead Helicobacter pylori.
Lancet, 350 (1997), pp. 71-72
[26.]
M. Karita, M.J. Blaser.
Aci-tolerance response in Helicobacter pylori and differences between cagA+and cagA– strains.
J Infect Dis, 178 (1998), pp. 213-219
[27.]
N. Broutet, A. Marais, H. Lamouliatte, A. Mascarel, R. Samoyeau, R. Salamon, et al.
cagA status and eradication treatment outcome of anti-Helicobacter pylori triple therapy therapies in patients with nonulcer dyspepsia.
J Clin Microbiol, 39 (2001), pp. 1319-1322
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos